Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2008

Luminex and BD Ally to Develop Tests for Cancer Prediction

  • Luminex and BD are joining forces to develop molecular diagnostics for certain cancers. BD Diagnostics-TriPath will develop, market, and sell these tests using Luminex’ multiplexing xMAP® Technology platform.

    BD develops technologies for cervical cancer screening as well as diagnostic products for the detection of cancer. The aim is to expand its offerings to include tests for solid tumor cancers using Luminex' platform.

    The xMAP Technology is a multiplexing platform that allows scientists to conduct multiple, simultaneous tests on one patient sample. “We believe providing biomarker testing in a multiplex format would allow detection of cancer at an earlier stage,” says Wayne Brinster, vp and GM of BD Diagnostics-TriPath.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »